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A solitary pulmonary nodule (SPN) or mass may 
either represent lung cancer or a benign disease such 
as pulmonary tuberculosis (TB). Most such lesions 
are incidental findings on a chest radiograph, and 
malignancy is generally actively excluded as it may 
represent curable disease.[1] As patients with metastatic disease usually 
do not qualify for resection, the correct assessment and provisional 
staging of lung cancer patients is crucial in guiding their further 
management. Integrated positron emission tomography/computed 
tomography (PET-CT) is an integral part of this diagnostic process, 
and has been shown to reduce the number of futile thoracotomies.[2]
The majority of studies on PET-CT have been conducted in 
areas with a low or moderate prevalence of TB, a disease which is 
well known to cause false-positive results.[3,4] Developing regions, 
particularly TB-endemic areas, therefore face a potential challenge of 
interpreting PET-CT images as false positive.[5,6]
The aim of this study was to assess the sensitivity, specificity, 
and diagnostic accuracy of integrated PET-CT in the evaluation 
of SPNs and masses in an area with a very high TB incidence. A 
secondary aim was to investigate which maximum standardised 
uptake value (SUVmax) cut-off would potentially be the most suitable 
in distinguishing between benign and malignant disease in a 
TB-endemic area. The overall objective of the study was to improve 
the management of pulmonary masses by preventing unnecessary 
thoracotomies for benign lesions.
Methods
Study population
All patients referred to the Division of Pulmonology at Tygerberg 
Academic Hospital, Cape Town, South Africa, from 2009 to 2012 
for evaluation of apparent SPNs or masses (1 - 6 cm in diameter) 
seen on routine chest radiographs and who subsequently underwent 
an integrated PET-CT were included. Patients who were found to 
have mediastinal lymph node involvement (not seen on routine 
chest radiography) on subsequent imaging (CT or PET-CT) were 
not excluded. Tygerberg Academic Hospital, a 1 380-bed aca-
demic hospital, is one of two academic referral centres in the city 
and renders a tertiary service to a population of approximately 
1.5 million. According to the 2014 World Health Organization report, 
this population has one of the highest incidence rates for TB, approxi-
mately 1 000 cases for every 100 000 people each year, and the third 
highest burden of disease globally after India and China.[7]
The study was approved by the Stellenbosch University Health 
Research Ethics Committee, and informed consent was obtained 
from all subjects prior to enrolment and prior to all invasive 
procedures.
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Background. Integrated positron emission tomography/computed tomography (PET-CT) is a well-validated modality for assessing 
pulmonary mass lesions and specifically for estimating risk of malignancy. Tuberculosis (TB) is known to cause false-positive PET-CT 
findings.
Objective. To investigate the utility of PET-CT in the evaluation of pulmonary mass lesions and nodules in a high TB prevalence setting.
Methods. All patients referred for the evaluation of a solitary pulmonary nodule or mass and who underwent PET-CT scanning over a 
3-year period were included. The PET-CT findings, including maximum standardised uptake value (SUVmax), were compared with the gold 
standard (tissue or microbiological diagnosis). The sensitivity, specificity, positive and negative predictive values and diagnostic accuracy 
for malignant disease were calculated according to the SUVmax cut-off of 2.5 and a proposed cut-off obtained from a receiver operating 
characteristic (ROC) curve.
Results. Forty-nine patients (mean (standard deviation) age 60.1 (10.2) years; 29 males) were included, of whom 30 had malignancy. 
Using an SUVmax cut-off of 2.5, PET-CT had a sensitivity, specificity, positive and negative predictive value and diagnostic accuracy for 
malignancy of 93.3%, 36.8%, 70.0%, 77.8% and 71.4%, respectively. After a ROC curve analysis, a suggested SUVmax cut-off of 5.0 improved 
the specificity to 78.9% and the diagnostic accuracy to 86.7%, with a small reduction in sensitivity to 90.0%.
Conclusions. The diagnostic accuracy of PET-CT in the evaluation of pulmonary mass lesions using the conventional SUVmax cut-off 
of 2.5 was reduced in a TB-endemic area. An SUVmax cut-off of 5.0 has a higher specificity and diagnostic accuracy for malignancy, with a 
comparable sensitivity.
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Imaging techniques
All studies were performed from the base of 
the skull to the upper thigh with a Siemens 
Biograph or Philips Gemini PET-CT with 
16-slice uncontrasted CT. The procedure 
was performed according to European Asso-
ciation of Nuclear Medicine guidelines. [8] 
Patients fasted, except for water intake, for 
at least 6 hours prior to the study. Blood 
glucose levels were tested prior to the scan, 
which was postponed if the patient had a 
level of >11.1 mmol/L. Patients lay supine 
for 30 minutes prior to the study, and 
for a further 60 minutes without talking 
after injection of 18F-fluorodeoxyglucose 
(FDG). An FDG dose of 7 - 13 mCi was 
administered according to body weight. All 
images were interpreted by an experienced 
nuclear medicine physician, at least one 
radiologist, and independently by a respira-
tory physician. Positivity was defined clini-
cally as any FDG uptake greater than the 
mediastinal blood pool. The intensity of 
the FDG uptake in an area of interest was 
quantified using a Philips EBW workstation. 
A cursor was manually placed at the site of 
highest visual uptake within the lymph node 
and the SUVmax was obtained from this slice 
using a circular region of interest with an 
8 mm diameter.
Tissue sampling
The final diagnosis was established by 
histo logical or cytological analysis of tissue 
samples acquired from the pulmonary 
mass lesion or mediastinal lymph nodes, 
depending on the results of the PET-
CT. Patients with a positive result for the 
pulmonary mass lesion on integrated PET-
CT and negative results for mediastinal 
lymph node (N0) and distant metastases 
(M0) then underwent tissue sampling 
procedures of the pulmonary mass lesion. 
This was performed using CT-guided fine-
needle aspiration, transthoracic ultrasound-
guided needle aspiration or excision biopsy/
lobar resection as indicated. Patients with 
a negative integrated PET-CT result for 
distant metastases and a positive result 
for mediastinal lymph node involvement 
(positive N-staging) underwent either 
endo scopic sampling of the mediastinal 
lymph nodes or tissue acquisition by 
mediastinoscopy, depending on their 
accessibility.
Because of the high negative predictive 
value of integrated PET-CT, negative 
N-staging and M-staging on PET-CT was 
considered to be a true negative. This was 
then confirmed with clinical and radiological 
follow-up. Each patient included in the 
study was also tested for Mycobacterium 
tuberculosis infection. This was done by 
Ziehl-Nielsen staining and culture of spu-
tum and/or bronchial washings, and/or 
histological proof of granulomatous tissue 
with necrosis, and/or culture of fine-needle 
aspirates.
Benign disease was defined as TB proven 
by the methods outlined above, histological 
confirmation of benign disease on lung 
resection, or clinical and radiological follow-
up for a period of at least 2 years showing 
no growth, disappearance or clear evidence 
of reduction in size of the pulmonary mass 
lesion.
Statistical analysis
The results of histological or cytological 
analysis, or proof of benign disease on 
radiological follow-up, were considered the 
gold standard and were correlated with the 
findings of the integrated PET-CT in order 
to obtain sensitivity, specificity, positive 
pre dictive value, negative predictive value 
and diagnostic accuracy of integrated PET-
CT. These were calculated by standard 
techniques, initially with an SUVmax cut-
off of 2.5. Thereafter a receiver operating 
characteristic (ROC) curve was obtained 
from the data set to determine an SUVmax 
cut-off that would provide the optimal 
sensitivity and specificity for our data set.
Results
Study population and diagnoses
Fifty patients fulfilled the inclusion criteria, 
but one was excluded owing to technical 
problems with acquisition of the PET study, 
leaving a study population of 49 patients 
(mean (standard deviation (SD)) age 60.1 
(10.2) years; 29 males). The final diagnoses 
are summarised in Table 1. Lung cancer was 
confirmed in 30 patients, and two patients 
were found to have carcinoid tumours. Of 
the patients with malignant lesions, 21/32 
(65.6%) were ultimately found to have 
resectable disease.
Chest radiograph and CT findings
The average diameters of the lesions meas-
ured were 29 mm in the vertical axis and 
30 mm in the horizontal axis on standard 
anteroposterior (AP) chest radiograph, 
and these were very similar to the CT 
measurements (Figs 1 and 2). Lesions ulti-
mately proven to be malignant were most 
frequently observed in the right (n=12) and 
left upper lobes (n=8).
Table 1. Final aetiology in all cases 
(N=49)
Type n (%)
Adenocarcinoma 19 (38.8)
Squamous cell carcinoma 7 (14.7)
Poorly differentiated carcinoma 2 (4.1)
Carcinoid 2 (4.1)
Active pulmonary TB 8 (16.3)
Other benign* 11 (22.4)
*Other benign diagnoses included solitary fibrous tumour 
(n=1), old granulomas (n=7), bronchiectasis (n=2) and 
Haemophilus influenzae infection (n=1).
Fig. 1. A: An example of a mass lesion in the left 
upper lobe seen on CT scan. B: PET-CT showed 
high FDG uptake with an SUVmax of 13.3. The final 
diagnosis in this case was squamous cell carcinoma.
A
B
Fig. 2. A: CT scan from a patient who presented 
with a mass lesion in the apical segment of the 
left lower lobe. B: PET-CT confirmed an FDG-
avid lesion with an SUVmax of 3.8. This patient 
was ultimately diagnosed with pulmonary TB.
A
B
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PET-CT findings and SUVmax
Malignant lesions had a higher mean (SD) 
SUVmax than lesions caused by TB (12.4 (6.7) 
v. 6.8 (5.2), p=0.032). When the SUVmax cut-
off of 2.5 was used, the sensitivity, specificity, 
positive predictive value, negative predictive 
value and diagnostic accuracy of integrated 
PET-CT were 93.3%, 36.8%, 70.0%, 77.8% 
and 71.4%, respectively (Table 2).
A ROC curve was then obtained by 
comparing each SUVmax with the gold stan-
dard (Fig. 3). A ROC curve with a statistically 
significant area under the curve was obtained 
(0.854 (95% confidence interval 0.741 - 0.968), 
p<0.01). From this curve we could obtain 
an SUVmax that provided optimal sensitivity 
and specificity to our test. With a cut-off 
of 5.0 the sensitivity, specificity, positive 
predictive value, negative predictive value and 
diagnostic accuracy of integrated PET-CT 
for malignancy were 90.0%, 78.9%, 87.1%, 
83.3% and 86.7%, respectively (Table 2). These 
analyses confirmed that an SUVmax cut-off 
of 5.0 improved the specificity of integrated 
PET-CT for cancer in our setting from 36.8% 
to 78.9% and the diagnostic accuracy from 
71.4% to 86.7%, with only a small reduction in 
sensitivity from 93.3% to 90.0%.
Discussion
We found PET-CT to have poor diagnostic 
accuracy in an area with a very high inci-
dence of TB. Moreover, an SUVmax threshold 
of 2.5 had a specificity of only 37%. However, 
a higher SUVmax cut-off of 5.0 increased the 
specificity to 79% and diagnostic accuracy 
from 71% to 87%, with only a marginal 
reduction in sensitivity from 93% to 90%.
International PET-CT data for the evalua-
tion of SPNs show higher accuracy for 
cancer in settings where the TB prevalence 
is substantially lower.[4,9] A recent meta-
analysis by Deppen et al.[4] on the ability of 
PET-CT to diagnose lung cancer accurately 
in areas with a moderate burden of infectious 
lung diseases found significant hetero geneity 
for sensitivity and specificity across studies. 
The authors reported a pooled sensitivity 
of 99% and specificity of 75%. Alarmingly, 
there was a 16% lower average adjusted 
specificity (61% v. 77%) in regions with 
endemic infectious lung disease compared 
with non-endemic regions.
Gould et al.[9] previously showed that PET 
is an accurate, non-invasive method for diag-
nosing an SPN in a developed world setting, 
with an overall sensitivity of 96.8% and a 
specificity of 77.8%. A retrospective study 
of 42 patients with SPNs in California found 
both an SUVmax cut-off of 2.0 and the visual 
interpretation yielded similar accuracy, with 
a sensitivity and specificity of 97% and 85%, 
respectively.[10]
In Brazil, with a TB incidence rate of 
66/100 000 population, the sensitivity and 
specificity of PET-CT (using an SUVmax cut-
off of 2.5) were found to be 92.9% and 72.2%, 
respectively.[11] Limited data exist for the 
evaluation of PET-CT in other TB-endemic 
areas. In a Chinese population this modality 
was found to have a sensitivity and specificity 
of 88.3% and 61.1%, respectively. [12] An 
SUVmax cut-off of 3.96 (determined by a ROC 
curve analysis) improved the sensitivity to 
73.3% and the specificity to 75.0% in this 
population.[12]
Only three studies have evaluated nuclear 
scanning to assess pulmonary mass lesions 
in SA.[6,13,14] Schuurmans et al.[13] found a 
sensitivity of 92.3% and a specificity of 91.7% 
for the use of technetium 99m-methoxy 
isobutyl isonitrile as a marker for tumour 
uptake. Sathekge et al.[6] performed a pro-
spective study of 30 patients to assess the 
accuracy of dual time point PET-CT in the 
assessment of SPNs in Pretoria, SA. Their 
analysis showed similar findings to our study 
with a sensitivity of 85.7% and a specificity 
of 25% when using an SUVmax cut-off of 2.5. 
When TB (n=12) was excluded from their 
analysis, the sensitivity improved to 85.7% 
and the specificity to 100%. The present 
study confirms the findings of Sathekge et 
al.[6] regarding poor specificity in an area 
with high TB prevalence. Moreover, our data 
suggest that an SUVmax of 5.0 may be a more 
appropriate cut-off value in an area with a 
high TB incidence, and additionally that 
values of 2.5 - 5.0 should be interpreted as 
indeterminate. In a recent study, Vorster et 
al.[14] demonstrated that 68Ga-citrate PET/
CT has potential for the detection of both 
malignancy and TB, but it seemed incapable 
of providing a clear distinction between 
malignant and benign lung lesions in a 
setting with a high prevalence of granulo-
matous diseases such as TB.
Importantly, it should be emphasised that 
the interpretation of PET-CT does not rely 
solely on SUV values. Swensen et al.,[15] for 
example, developed a pretest probability 
model using age, smoking history, history 
Table 2. Respective diagnostic accuracies of SUVmax cut-offs of 2.5 and 5.0
SUVmax 2.5, % (95% CI) SUVmax 5.0, % (95% CI)
Sensitivity 93.3 (76.5 - 98.8) 90.0 (72.3 - 97.4)
Specificity 36.8 (17.2 - 61.4) 78.9 (53.9 - 93.0)
PPV 70.0 (53.3 - 82.9) 87.1 (69.2 - 95.8)
NPV 77.8 (40.2 - 96.1) 83.3 (57.7 - 95.6)
PPV = positive predictive value; NPV = negative predictive value.
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Fig. 3. The ROC curve, annotated with the SUVmax cut-off values of 2.5 and 5.0 (see text for details).
RESEARCH
1052       December 2015, Vol. 105, No. 12
of extrathoracic cancer more than 5 years before nodule detection, 
nodule diameter, upper lobe location and spiculated margin. They 
achieved an area under the ROC curve of 0.80. Li et al.[16] developed 
a mathematical model for predicting malignancy using age, diameter, 
border calcification, spiculation, and family history of tumour. Their 
model generated a sensitivity of 94.5% and a specificity of 70.0%. Tian 
et al.[17] included FDG uptake as a variable in developing a prediction 
model by logistic regression analysis. They used gender, smoking history, 
age, diameter, spiculation and FDG uptake to estimate the probability of 
malignancy of SPNs. Using a cut-off value determined by ROC curve 
analysis, they achieved a sensitivity of 90.2% and a specificity of 87.6%. 
PET-CT is therefore not a stand-alone investigation, but can contribute 
to the determination of malignant probability. Such a model could 
potentially be developed in a TB-endemic area.
A potential weakness of this study is the inclusion of a small 
proportion of patients initially assessed to have solitary pulmonary 
mass lesions or nodules on chest radiograph, who were later found to 
have more extensive disease on CT or PET-CT. Moreover, a limitation 
of increasing the SUVmax to 5.0 is that a number of lung malignancies 
with low metabolic activity (such as adenocarcinoma in situ) may be 
falsely reported as negative, whereas some tuberculous lesions (which 
may demonstrate higher SUVmax values) may be interpreted as positive.
In conclusion, the reduced specificity for malignancy of PET-CT 
in TB-endemic areas can be significantly improved by using an 
optimised threshold for SUVmax. PET-CT is a valuable adjunct in the 
assessment of patients with a pulmonary mass lesion on presentation, 
provided other clinical and radiological evidence is integrated in 
the assessment. Further research on integrating various SUVs with 
clinical and radiological prediction scores in settings with a high 
prevalence of TB is needed.
Acknowledgments. Tonya Esterhuizen of the Centre for Evidence-
based Health Care, Stellenbosch University, performed the independent 
statistical analysis of study data.
References 
1. Swensen S, Jett J, Payne W, et al. An integrated approach to evaluation of the solitary pulmonary 
nodule. Mayo Clin Proc 1990;65(2):173-186. [http://dx.doi.org:/10.1016/s0025-6196(12)65012-5]
2. Fischer B, Lassen U, Mortensen J, et al. Preoperative staging of lung cancer with combined PET-CT. N 
Engl J Med 2009;361(1):32-39. [http://dx.doi.org/10.1056/nejmoa0900043]
3. Shaw JA, Irusen EM, von Groote-Bidlingmaier F, et al. Integrated positron emission tomography/
computed tomography for evaluation of mediastinal lymph node staging of non-small-cell lung cancer 
in a tuberculosis-endemic area: A 5-year prospective observational study. S Afr Med J 2015;105(2):145-
150. [http://dx.doi.org/10.7196/SAMJ.8357]
4. Deppen SA, Blume JD, Kensinger CD, et al. Accuracy of FDG-PET to diagnose lung cancer in areas with 
infectious lung disease. JAMA 2014;312(12):1227-1236. [http://dx.doi.org/10.1001/jama.2014.11488]
5. Chang J, Lee H, Goo J, et al. False positive and false negative FDG-PET scans in various thoracic 
diseases. Korean J Radiol 2006;7(1):57-69. [http://dx.doi.org/10.3348/kjr.2006.7.1.57]
6. Sathekge M, Maes A, Pottel H, Stoltz A, van de Wiele C. Dual time-point FDG PET-CT for 
differentiating benign from malignant solitary pulmonary nodules in a TB endemic area. S Afr Med 
J 2010;100(9):598-601.
7. World Health Organization. WHO Global Tuberculosis Report 2014. http://www.who.int/tb/
publications/global_report/en (accessed 15 February 2015).
8. Boellaard R, O’Doherty M, Weber W, et al. EANM procedure guidelines for tumour PET imaging: 
Version 1.0. Eur J Nucl Med Mol Imaging 2010;37(1):181-200. [http://dx.doi.org/10.1007/s00259-009-
1297-4]
9. Gould M, Maclean C, Kuschner W, Rydzak C, Owens D. Accuracy of positron emission tomography 
for diagnosis of pulmonary nodules and mass lesions: A meta-analysis. JAMA 2001;285(7):914-924. 
[http://dx.doi.org/10.1001/jama.285.7.914]
10. Kim S, Allen-Auerbach M, Goldin J, et al. Accuracy of PET/CT in characterization of solitary 
pulmonary lesions. J Nucl Med 2007;48(2):214-220.
11. Martins Rde C, Almeida S, Siciliano A, et al. Value of [18F]-FDG-PET/CT as a predictor of cancer 
in solitary pulmonary nodule. J Bras Pneumol 2008;34(7):473-480. [http://dx.doi.org/10.1590/s1806-
37132008000700007]
12. Li Y, Su M, Li F, Kuang A, Tian R. The value of 18F-FDG-PET/CT in the differential diagnosis of solitary 
pulmonary nodules in areas with a high incidence of tuberculosis. Ann Nucl Med 2011;25(10):804-
811. [http://dx.doi.org/10.1007/s12149-011-0530-y]
13. Schuurmans M, Ellmann A, Bouma H, et al. Solitary pulmonary nodule evaluation with 99mTc-
methoxy isobutyl isonitrile in a tuberculosis-endemic area. Eur Respir J 2007;30(6):1090-1095. [http://
dx.doi.org/10.1183/09031936.00046107]
14. Vorster M, Maes A, Jacobs A, et al. Evaluating the possible role of 68Ga-citrate PET/CT in the 
characterization of indeterminate lung lesions. Ann Nucl Med 2014;28(6):523-530. [http://dx.doi.
org/10.1007/s12149-014-0842-9]
15. Swensen S, Silverstein M, Ilstrup D, Schleck C, Edell E. The probability of malignancy in solitary 
pulmonary nodules: Application to small radiologically indeterminate nodules. Arch Intern Med 
1997;157(8):849-855. [http://dx.doi.org/10.1001/archinte.1997.00440290031002]
16. Li Y, Wang J. A mathematical model for predicting malignancy of solitary pulmonary nodules. World 
J Surg 2012;36(4):830-835. [http://dx.doi.org/10.1007/s00268-012-1449-8]
17. Tian R, Su M, Tian Y, Li F, Kuang A. Development of a predicting model to estimate the probability 
of malignancy of solitary pulmonary nodules. Sichuan Da Xue Xue Bao Yi Xue Ban 2012;43:404-408. 
[http://dx.doi.org/10.1016/j.cllc.2011.06.005] 
Accepted 5 November 2014.
